How much revenue did Emmaus Life Sciences generate this year?
Emmaus Life Sciences has achieved a revenue of 21.73 M USD this year.
Emmaus Life Sciences Revenue 2024
Emmaus Life Sciences Revenue
21.73 M USD
Ticker
EMMA
ISIN
US29137T1016
WKN
A2PNWG
In 2024, Emmaus Life Sciences's sales reached 21.73 M USD, a -26.57% difference from the 29.6 M USD sales recorded in the previous year.
The Emmaus Life Sciences Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2026e | 38.04 | 74,27 |
| 2025e | 23.25 | 121,51 |
| 2024e | 21.73 | 130,01 |
| 2023 | 29.6 | 95,47 |
| 2022 | 18.39 | 85,92 |
| 2021 | 20.61 | 83,94 |
| 2020 | 23.17 | 90,29 |
| 2019 | 22.75 | 95,21 |
| 2018 | 1.32 | 37,12 |
| 2017 | 0.13 | 61,54 |
| 2016 | 0.09 | 88,89 |
| 2015 | 0.1 | 100,00 |
| 2014 | 0.14 | 42,86 |
| 2013 | 0.13 | -7,69 |
| 2012 | 0.12 | -16,67 |
| 2011 | 0.11 | -36,36 |
| 2010 | 0.64 | 78,13 |
| 2009 | 0.7 | 81,43 |
| 2008 | 0.77 | 79,22 |
| 2007 | 0.24 | 29,17 |
| 2006 | - | - |
| 2005 | - | - |
| 2004 | - | - |
Emmaus Life Sciences Revenue, EBIT, Net Income US29137T1016 · A2PNWG
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Emmaus Life Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Emmaus Life Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Emmaus Life Sciences’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Emmaus Life Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Emmaus Life Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Emmaus Life Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Emmaus Life Sciences’s growth potential.
Emmaus Life Sciences Revenue, EBIT and net profit per share
| Date | Emmaus Life Sciences Revenue | Emmaus Life Sciences EBIT | Emmaus Life Sciences Net Income |
|---|---|---|---|
| 2026e | 38.04 M undefined | 4.44 M undefined | 4.83 M undefined |
| 2025e | 23.25 M undefined | -5.59 M undefined | -3.79 M undefined |
| 2024e | 21.73 M undefined | -5.58 M undefined | 2.52 M undefined |
| 2023 | 29.6 M undefined | 3.54 M undefined | -3.73 M undefined |
| 2022 | 18.39 M undefined | -6.59 M undefined | -10.63 M undefined |
| 2021 | 20.61 M undefined | -6.12 M undefined | -15.95 M undefined |
| 2020 | 23.17 M undefined | -30,000 undefined | 1.35 M undefined |
| 2019 | 22.75 M undefined | -4.51 M undefined | -54.84 M undefined |
| 2018 | 1.32 M undefined | -10.24 M undefined | -9.6 M undefined |
| 2017 | 130,000 undefined | -7.1 M undefined | -7.11 M undefined |
| 2016 | 90,000 undefined | -3.77 M undefined | -5.94 M undefined |
| 2015 | 100,000 undefined | -2.66 M undefined | -3.38 M undefined |
| 2014 | 140,000 undefined | -3.82 M undefined | -2.66 M undefined |
| 2013 | 130,000 undefined | -4.2 M undefined | -10.91 M undefined |
| 2012 | 120,000 undefined | -4.81 M undefined | -3.41 M undefined |
| 2011 | 110,000 undefined | -5.29 M undefined | -8.87 M undefined |
| 2010 | 640,000 undefined | -6.51 M undefined | -8.17 M undefined |
| 2009 | 700,000 undefined | -6.37 M undefined | -8.52 M undefined |
| 2008 | 770,000 undefined | -5.47 M undefined | -5.37 M undefined |
| 2007 | 240,000 undefined | -3.27 M undefined | -3.28 M undefined |
| 2006 | 0 undefined | -420,000 undefined | -440,000 undefined |
| 2005 | 0 undefined | -30,000 undefined | -20,000 undefined |
| 2004 | 0 undefined | -260,000 undefined | -270,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 0 USD | -260,000 USD | -270,000 USD |
| 2005 | 0 USD | -30,000 USD | -20,000 USD |
| 2006 | 0 USD | -420,000 USD | -440,000 USD |
| 2007 | 240,000 USD | -3.27 M USD | -3.28 M USD |
| 2008 | 770,000 USD | -5.47 M USD | -5.37 M USD |
| 2009 | 700,000 USD | -6.37 M USD | -8.52 M USD |
| 2010 | 640,000 USD | -6.51 M USD | -8.17 M USD |
| 2011 | 110,000 USD | -5.29 M USD | -8.87 M USD |
| 2012 | 120,000 USD | -4.81 M USD | -3.41 M USD |
| 2013 | 130,000 USD | -4.2 M USD | -10.91 M USD |
| 2014 | 140,000 USD | -3.82 M USD | -2.66 M USD |
| 2015 | 100,000 USD | -2.66 M USD | -3.38 M USD |
| 2016 | 90,000 USD | -3.77 M USD | -5.94 M USD |
| 2017 | 130,000 USD | -7.1 M USD | -7.11 M USD |
| 2018 | 1.32 M USD | -10.24 M USD | -9.6 M USD |
| 2019 | 22.75 M USD | -4.51 M USD | -54.84 M USD |
| 2020 | 23.17 M USD | -30,000 USD | 1.35 M USD |
| 2021 | 20.61 M USD | -6.12 M USD | -15.95 M USD |
| 2022 | 18.39 M USD | -6.59 M USD | -10.63 M USD |
| 2023 | 29.6 M USD | 3.54 M USD | -3.73 M USD |
| 2024e | 21.73 M USD | -5.58 M USD | 2.52 M USD |
| 2025e | 23.25 M USD | -5.59 M USD | -3.79 M USD |
| 2026e | 38.04 M USD | 4.44 M USD | 4.83 M USD |
Emmaus Life Sciences stock margins US29137T1016 · A2PNWG
The Emmaus Life Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Emmaus Life Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Emmaus Life Sciences.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Emmaus Life Sciences's sales revenue. A higher gross margin percentage indicates that the Emmaus Life Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Emmaus Life Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Emmaus Life Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Emmaus Life Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Emmaus Life Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Emmaus Life Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Emmaus Life Sciences Margin History
| Emmaus Life Sciences Gross margin | Emmaus Life Sciences Profit margin | Emmaus Life Sciences EBIT margin | Emmaus Life Sciences Profit margin |
|---|---|---|---|
| 2026e | 95.47 % | 11.68 % | 12.7 % |
| 2025e | 95.47 % | -24.05 % | -16.28 % |
| 2024e | 95.47 % | -25.68 % | 11.61 % |
| 2023 | 95.47 % | 11.96 % | -12.61 % |
| 2022 | 85.92 % | -35.83 % | -57.8 % |
| 2021 | 83.94 % | -29.69 % | -77.39 % |
| 2020 | 90.29 % | -0.13 % | 5.83 % |
| 2019 | 95.21 % | -19.82 % | -241.05 % |
| 2018 | 37.12 % | -775.76 % | -727.27 % |
| 2017 | 61.54 % | -5,461.54 % | -5,469.23 % |
| 2016 | 88.89 % | -4,188.89 % | -6,600 % |
| 2015 | 100 % | -2,660 % | -3,380 % |
| 2014 | 42.86 % | -2,728.57 % | -1,900 % |
| 2013 | -7.69 % | -3,230.77 % | -8,392.31 % |
| 2012 | -16.67 % | -4,008.33 % | -2,841.67 % |
| 2011 | -36.36 % | -4,809.09 % | -8,063.64 % |
| 2010 | 78.13 % | -1,017.19 % | -1,276.56 % |
| 2009 | 81.43 % | -910 % | -1,217.14 % |
| 2008 | 79.22 % | -710.39 % | -697.4 % |
| 2007 | 29.17 % | -1,362.5 % | -1,366.67 % |
| 2006 | 95.47 % | 0 % | 0 % |
| 2005 | 95.47 % | 0 % | 0 % |
| 2004 | 95.47 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 95.47 % | 0 % | 0 % |
| 2005 | 95.47 % | 0 % | 0 % |
| 2006 | 95.47 % | 0 % | 0 % |
| 2007 | 29.17 % | -1,362.5 % | -1,366.67 % |
| 2008 | 79.22 % | -710.39 % | -697.4 % |
| 2009 | 81.43 % | -910 % | -1,217.14 % |
| 2010 | 78.13 % | -1,017.19 % | -1,276.56 % |
| 2011 | -36.36 % | -4,809.09 % | -8,063.64 % |
| 2012 | -16.67 % | -4,008.33 % | -2,841.67 % |
| 2013 | -7.69 % | -3,230.77 % | -8,392.31 % |
| 2014 | 42.86 % | -2,728.57 % | -1,900 % |
| 2015 | 100 % | -2,660 % | -3,380 % |
| 2016 | 88.89 % | -4,188.89 % | -6,600 % |
| 2017 | 61.54 % | -5,461.54 % | -5,469.23 % |
| 2018 | 37.12 % | -775.76 % | -727.27 % |
| 2019 | 95.21 % | -19.82 % | -241.05 % |
| 2020 | 90.29 % | -0.13 % | 5.83 % |
| 2021 | 83.94 % | -29.69 % | -77.39 % |
| 2022 | 85.92 % | -35.83 % | -57.8 % |
| 2023 | 95.47 % | 11.96 % | -12.61 % |
| 2024e | 95.47 % | -25.68 % | 11.61 % |
| 2025e | 95.47 % | -24.05 % | -16.28 % |
| 2026e | 95.47 % | 11.68 % | 12.7 % |
Emmaus Life Sciences Aktienanalyse
What does Emmaus Life Sciences do?
Emmaus Life Sciences Inc. is an innovative US-American company that develops, produces, and markets medications based on L-Glutamine. The company was founded in 2000 by Dr. Yutaka Niihara, a Japanese researcher who grew up in the USA and received his doctorate from Harvard Medical School. The idea for founding Emmaus Life Sciences arose from the observation of patients with sickle cell anemia, an inherited blood disease. These patients suffer from intense pain attacks caused by the clumping of red blood cells in the body. Dr. Niihara and his colleagues researched the effects of L-Glutamine on these pain attacks and were able to demonstrate that L-Glutamine can significantly reduce the frequency and intensity of the pain attacks. Based on these research results, Emmaus Life Sciences developed the medication "Endari," which was approved by the US-American regulatory authority FDA in 2017. "Endari" is the first medication specifically approved for the treatment of sickle cell anemia. It is intended to reduce the frequency and severity of pain attacks in patients with sickle cell anemia. Since its founding in 2000, Emmaus Life Sciences has expanded significantly. The company now has multiple locations in the USA and employs over 150 employees. Emmaus Life Sciences operates in two business areas: medications and health products. In the medication area, Emmaus Life Sciences focuses on the development of drugs for rare diseases. In addition to "Endari," the company is working on the development of medications for the treatment of mucopolysaccharidosis (MPS) and acid peptidase deficiency (ASM). In the health products area, Emmaus Life Sciences specializes in the production and marketing of dietary supplements. The company has developed a range of products based on L-Glutamine as the active ingredient. These products are intended to support the health of athletes, people with special dietary needs, older adults, and people with certain diseases. Emmaus Life Sciences' products include L-Glutamine powder for daily use, L-Glutamine capsules for athletes and bodybuilders, L-Glutamine for clinical nutrition, and a special L-Glutamine product for people with chronic kidney disease. Emmaus Life Sciences is an innovative company that builds its products on scientifically validated research results. The company specializes in the development of medications and health products that help people improve their health and increase their quality of life. Emmaus Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Emmaus Life Sciences's Sales Figures
The sales figures of Emmaus Life Sciences originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Emmaus Life Sciences’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Emmaus Life Sciences's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Emmaus Life Sciences’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Emmaus Life Sciences stock
How much was the turnover of the company Emmaus Life Sciences compared to the previous year?
The revenue of Emmaus Life Sciences has increased by -26.57% decreased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Emmaus Life Sciences?
The revenue of Emmaus Life Sciences is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Emmaus Life Sciences measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Emmaus Life Sciences so important for investors?
The revenue of Emmaus Life Sciences is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Emmaus Life Sciences pay?
Over the past 12 months, Emmaus Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Emmaus Life Sciences is expected to pay a dividend of 0 USD.
What is the dividend yield of Emmaus Life Sciences?
The current dividend yield of Emmaus Life Sciences is .
When does Emmaus Life Sciences pay dividends?
Emmaus Life Sciences pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Emmaus Life Sciences?
Emmaus Life Sciences paid dividends every year for the past 0 years.
What is the dividend of Emmaus Life Sciences?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Emmaus Life Sciences located?
Emmaus Life Sciences is assigned to the 'Health' sector.
Wann musste ich die Aktien von Emmaus Life Sciences kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Emmaus Life Sciences from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.
When did Emmaus Life Sciences pay the last dividend?
The last dividend was paid out on 9/10/2024.
What was the dividend of Emmaus Life Sciences in the year 2023?
In the year 2023, Emmaus Life Sciences distributed 0 USD as dividends.
In which currency does Emmaus Life Sciences pay out the dividend?
The dividends of Emmaus Life Sciences are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Emmaus Life Sciences
Our stock analysis for Emmaus Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Emmaus Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Emmaus Life Sciences Revenue
- Emmaus Life Sciences Net Income
- Emmaus Life Sciences P/E
- Emmaus Life Sciences P/S
- Emmaus Life Sciences EBIT
- Emmaus Life Sciences Dividend
- Emmaus Life Sciences Stocks
- Emmaus Life Sciences Market capitalization
- Emmaus Life Sciences Debt
- Emmaus Life Sciences Liabilities
- Emmaus Life Sciences Equity
- Emmaus Life Sciences AAQS
- Emmaus Life Sciences Employees
- Emmaus Life Sciences ROE
- Emmaus Life Sciences ROA
- Emmaus Life Sciences ROCE
